Derivation of Clinically Compliant MSCs from CD105+, CD24− Differentiated Human ESCs

Lian, Qizhou; Lye, Elias; Yeo, Keng Suan; Tan, Eileen Khia Way; Salto–Tellez, Manuel; Liu, Tongming; Palanisamy, Nallasivam; Oakley, Reida El; Lee, Eng Hin; Lim, Bing; Lim, Sai‐Kiang

doi:10.1634/stemcells.2006-0420

Cited by 296 publications

(279 citation statements)

References 45 publications

(78 reference statements)

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…Recently, Barberi et al generated an MSC population from human embryonic stem cells by coculturing with bone marrow-derived mouse stromal cells (OP9) [14]. MSCs have also been derived from hES cells without feeder layer support [13,[34][35][36]. In the present work, we have demonstrated in vitro and in vivo mesenchymal differentiation and tissue formation from human embryonic germ-derived cells.…”

Section: Discussionmentioning

confidence: 49%

Engineering Musculoskeletal Tissues with Human Embryonic Germ Cell Derivatives

et al. 2010

View full text Add to dashboard Cite

The cells derived from differentiating embryoid bodies of human embryonic germ (hEG) cells express a broad spectrum of gene markers and have been induced toward ectoand endodermal lineages. We describe here in vitro and in vivo differentiation of hEG-derived cells (LVEC line) toward mesenchymal tissues. The LVEC cells express many surface marker proteins characteristic of mesenchymal stem cells and differentiated into cartilage, bone, and fat. Homogenous hyaline cartilage was generated from cells after 63 population doublings. In vivo results demonstrate cell survival, differentiation, and tissue formation. The high proliferative capacity of hEG-derived cells and their ability to differentiate and form three-dimensional mesenchymal tissues without teratoma formation underscores their significant potential for regenerative medicine. The adopted coculture system also provides new insights into how a microenvironment comprised of extracellular and cellular components may be harnessed to generate hierarchically complex tissues from pluripotent cells. STEM CELLS 2010;28:765-774 Disclosure of potential conflicts of interest is found at the end of this article.

show abstract

Section: Discussionmentioning

confidence: 49%

Engineering Musculoskeletal Tissues with Human Embryonic Germ Cell Derivatives

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, that methodology was based on culturing MSCs from human ESCs that were grown into a thick multilayer epithelium. More recently, Lian et al reported generating MSCs from H1 and H9 human ESCs by culturing ESC colonies on gelatinized plates in knockout DMEM and supplemented with 10% serum replacement, FGF2 and PDGF AB followed by cell sorting for CD105+ and CD24-cells by FACS [18], which is different from our method. SSEA-4 is one of the markers expressed on undifferentiated human ESCs [26].…”

Section: Discussionmentioning

confidence: 86%

“…More recently, MSCs have also been derived from human embryonic stem cells (ESCs) either through co-culturing with the OP9 murine bone marrow stromal cell line or directly from ESCs cultured without feeder cells [17][18][19][20]. Human ESCs could potentially provide an unlimited source of MSCs for clinical applications.…”

Section: Introductionmentioning

confidence: 99%

Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells

Trivedi

Hematti

2008

Experimental Hematology

175

159

View full text Add to dashboard Cite

Objective-We have previously shown the simultaneous generation of CD73+ mesenchymal stromal cells (MSCs) along with CD34+ hematopoietic cells from human embryonic stem cells (ESCs) when they are co-cultured with OP9 murine stromal cells. We investigated whether MSCs can be derived from human ESCs without co-culturing with OP9 cells, and if such cells exhibit immunological properties similar to MSCs derived from adult human bone marrow (BM).Materials and Methods-Our starting populations were undifferentiated ESCs cultured on matrigel-coated plates without feeder cells. The differentiated fibroblast-looking cells were tested for expression of MSC markers and their potential for multi-lineage differentiation. We investigated surface expression of HLA molecules on these MSCs before and after treatment with interferon gamma (IFN-γ). We also tested the proliferative response of T-lymphocytes towards MSCs and the effects of MSCs in mixed lymphocyte reaction (MLR) assays. Conclusions-MSCs can be derived from human ESCs without feeder cells. These human ESCderived MSCs have cell surface markers, differentiation potentials, and immunological properties in vitro that are similar to adult BM-derived MSCs. Results-We

show abstract

“…As such, they are considered an ideal source of cells for regenerative medicine. It has been shown that hESCs can differentiate into cells with an MSC-like phenotype (Barberi et al, 2005;Lian et al, 2007;Olivier et al, 2006;Trivedi and Hematti, 2007). This particular source of MSCs is infinite and eliminates the need for potentially harmful invasive procedures.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effects of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells in Transient Focal Cerebral Ischemia in Rats

Liu

Seçkin

İzci

et al. 2009

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Embryonic mesenchymal stem cells (eMSCs) were first derived from human embryonic stem cells (hESCs) overexpressing green fluorescence protein (GFP). They expressed CD29, CD44, CD73, CD105, CD166 and nestin, but not CD34, CD45, CD106 SSEA-4 or Oct3/4. Twenty million eMSCs in 1 mL of phosphate-buffered saline (PBS) were injected into the femoral veins of spontaneously hypertensive rats after transient middle cerebral artery occlusion. The migration and differentiation of the eMSCs in the ischemic brain were analyzed. The results revealed that eMSCs migrated to the infarction region and differentiated into neurons, which were positive for b-tubulin III, microtubule-associated protein 2 (MAP2), HuC, neurofilament and human nuclear antibody, and to vascular endothelial cells, which were positive for von Willebrand factor (vWF). The transplanted cells survived in the infarction region for at least 4 weeks. Adhesive removal function significantly improved in the first week after cell transplantation, and rotarod motor function significantly improved starting from the second week. The infarction volume in the eMSC group was significantly smaller than that in the PBS control group at 4 weeks after infusion. The results of this study show that when administered intravenously, eMSCs differentiated into neuronal and endothelial cells, reduced the infarction volume, and improved behavioral functional outcome significantly in transient focal cerebral ischemia.

show abstract

Derivation of Clinically Compliant MSCs from CD105+, CD24− Differentiated Human ESCs

Cited by 296 publications

References 45 publications

Engineering Musculoskeletal Tissues with Human Embryonic Germ Cell Derivatives

Engineering Musculoskeletal Tissues with Human Embryonic Germ Cell Derivatives

Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells

Neuroprotective Effects of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells in Transient Focal Cerebral Ischemia in Rats

Contact Info

Product

Resources

About